AMGEN BIDS $167M TO BUY DRUG DISCOVERY SHOP NUEVOLUTION

Amgen has offered to buy Nuevolution for $167 million USD (€150 million). The takeover will give Amgen control of a drug discovery platform that landed Nuevolution deals with leading companies plus a pipeline of early-stage cancer and inflammation programs.

Why this matters: Denmark’s Nuevolution made a name for itself over the past decade through a series of deals with major drugmakers including GlaxoSmithKline, Johnson & Johnson, Merck and Novartis. In parallel, Nuevolution began using its drug discovery platform to generate internal candidates against targets including RORγt, BET and IL-17A.